Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022104 (
irritable bowel syndrome
)
8,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objective:
Acute gastroenteritis
(
AGE
) is a risk factor for post-infectious
irritable bowel syndrome
(PI-IBS). This systematic review evaluates the prevalence and risk-factors of PI-
IBS
after
AGE
by specific pathogens.
Materials and methods:
Medline (1966-2019) and Embase (1974-2019) were searched for studies evaluating PI-
IBS
minimum 3 months after
AGE
with
Campylobacter
spp.,
Salmonella
spp.,
Shigella
spp.,
Escherischia coli
,
Clostridium difficile
, norovirus, rotavirus,
Cryptosporidium
spp. or
Giardia intestinalis
using validated criteria for
IBS
. Pooled prevalence (PP), odds ratios (OR) and risk factors were determined for single pathogens, groups of bacteria, viruses and parasites, and overall for
AGE
caused by any pathogen. Random-effect models were used for meta-analyses.
Results:
A total of 34 articles were included. PP of PI-
IBS
after
Campylobacter
spp. was 12% (confidence interval 95% [CI]: 10-15%), Salmonellosis 12% (CI: 9-15%), Shigellosis 11% (CI: 8-15%),
C. difficile
14% (CI: 4-29%) and
E. coli
spp. 12% (CI: 5-20%). OR of PI-
IBS
after salmonellosis was 5.5 (CI: 2.3-12.8) and after shigellosis 13.8 (CI: 4.2-45.4). Bacterial
AGE
overall showed OR 5.8 (CI: 4.0-8.3) and
AGE
caused by any pathogen OR 4.9 (CI: 3.9-6.1). Few studies exist on viral and parasitic gastroenteritis.
Conclusions:
Current literature show similar risks for bacterial pathogens. Studies are limited for viral and parasitic pathogens. The evaluated risk-factors for PI-
IBS
varied among the included studies and the existing evidence is insufficient to identify pathogen-specific risk factors.
...
PMID:Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome? 3111 63
Irritable bowel syndrome
(
IBS
) is an extremely common and often very debilitating chronic functional gastrointestinal disorder. Despite its prevalence, significant associated healthcare costs, and quality-of-life issues for affected individuals, our understanding of its etiology remained limited. However, it is now evident that microbial factors play key roles in
IBS
pathophysiology.
Acute gastroenteritis
following exposure to pathogens can precipitate the development of
IBS
, and studies have demonstrated changes in the gut microbiome in
IBS
patients. These changes may explain some of the symptoms of
IBS
, including visceral hypersensitivity, as gut microbes exert effects on the host immune system and gut barrier function, as well as the brain-gut axis. Microbial differences also appear to underlie the two main functional categories of
IBS
: diarrhea-predominant
IBS
(IBS-D) is associated with small intestinal bacterial overgrowth, which can be diagnosed by a positive hydrogen breath test, and constipation-predominant
IBS
(IBS-C) is associated with increased levels of methanogenic archaea, which can be diagnosed by a positive methane breath test. Mechanistically, the pathogens that cause gastroenteritis and trigger subsequent
IBS
development produce a common toxin, cytolethal distending toxin B (CdtB), and antibodies raised against CdtB cross-react with the cytoskeletal protein vinculin and impair gut motility, facilitating bacterial overgrowth. In contrast, methane gas slows intestinal contractility, which may facilitate the development of constipation. While antibiotics and dietary manipulations have been used to relieve
IBS
symptoms, with varying success, elucidating the specific mechanisms by which gut microbes exert their effects on the host may allow the development of targeted treatments that may successfully treat the underlying causes of
IBS
.
...
PMID:Microbiome and Its Role in Irritable Bowel Syndrome. 3202 78